Avalyn Pharma

Avalyn Pharma

Avalyn Pharma operates as a clinical-stage biotechnology firm targeting interstitial lung diseases, most notably idiopathic pulmonary fibrosis (IPF). The company believes that delivering existing antifibrotic compounds directly to the lungs via inhalation can improve efficacy and reduce the side effects—such as gastrointestinal distress and liver toxicity—that limit patient compliance with current oral standards of care. Avalyn has advanced two lead inhaled programs: AP01, a reformulation of pirfenidone, and AP02, a reformulation of nintedanib, the two FDA-approved oral therapies for IPF. The firm deploys capital entirely into its own therapeutic pipeline, with no external fund commitments or balance-sheet investment strategy. Clinical progress has demonstrated proof of principle: Phase 1b data for AP01, presented at the 2022 European Respiratory Society Congress, showed numerically lower rates of treatment-emergent adverse events compared with historical oral pirfenidone data, alongside a pharmacokinetic profile consistent with a lung-targeted effect. The company subsequently initiated the ATLAS Phase 2b study, enrolling subjects across sites in the United States and Europe (per the firm's regulatory filings). Avalyn raised follow-on financing to fund these mid-stage trials, closing a $131 million Series B in January 2022 co-led by new investors Eventide Asset Management and Vivo Capital, with participation from existing backers Horizons Ventures, Samsara BioCapital, and Surveyor Capital. A previously undisclosed $35.5 million Series A supported early clinical work. As of its most recent structured disclosures, the firm reports fewer than 50 professionals, maintaining a lean footprint without the commercial infrastructure of a fully integrated pharmaceutical company. Structural differentiation stems from Avalyn’s narrow asset-selection logic: it does not pursue novel targets but instead improves the therapeutic window of validated mechanisms through dose-form innovation. This reduces biological risk relative to first-in-class pulmonary fibrosis programs while creating a known regulatory pathway via 505(b)(2) development. Governance is venture-backed and board-controlled, with the firm following a standard biotech exit trajectory rather than a perpetual family-office structure.